BR112018013677A2 - proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas - Google Patents

proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas

Info

Publication number
BR112018013677A2
BR112018013677A2 BR112018013677A BR112018013677A BR112018013677A2 BR 112018013677 A2 BR112018013677 A2 BR 112018013677A2 BR 112018013677 A BR112018013677 A BR 112018013677A BR 112018013677 A BR112018013677 A BR 112018013677A BR 112018013677 A2 BR112018013677 A2 BR 112018013677A2
Authority
BR
Brazil
Prior art keywords
multivalent
multispecific
fusion proteins
binding fusion
bind
Prior art date
Application number
BR112018013677A
Other languages
English (en)
Inventor
Hussain Abrahim
S Razai Amir
P Eckelman Brendan
Becklund Bryan
Hata Chelsie
C Timmer John
S Jones Kyle
Rason Lucas
Kaplan Mike
Deveraux Quinn
Pandit Rajay
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of BR112018013677A2 publication Critical patent/BR112018013677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)

Abstract

esta invenção refere-se geralmente a moléculas que se ligam especificamente a 41bb, um membro da superfamília de receptores de tnf (tnfrsf). mais especificamente, esta invenção refere-se a moléculas multivalentes e multiespecíficas que se ligam a pelo menos 41bb.
BR112018013677A 2016-01-11 2017-01-11 proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas BR112018013677A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277028P 2016-01-11 2016-01-11
PCT/US2017/013040 WO2017123650A2 (en) 2016-01-11 2017-01-11 Multivalent and multispecific 41bb-binding fusion proteins

Publications (1)

Publication Number Publication Date
BR112018013677A2 true BR112018013677A2 (pt) 2019-01-22

Family

ID=59275541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013677A BR112018013677A2 (pt) 2016-01-11 2017-01-11 proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas

Country Status (12)

Country Link
US (3) US10501551B2 (pt)
EP (1) EP3402823A4 (pt)
JP (2) JP7022993B2 (pt)
KR (1) KR20180096789A (pt)
CN (1) CN108779176A (pt)
AU (2) AU2017207742B2 (pt)
BR (1) BR112018013677A2 (pt)
CA (1) CA3009661A1 (pt)
IL (2) IL260530B2 (pt)
MX (1) MX2018008308A (pt)
SG (2) SG10201912405TA (pt)
WO (1) WO2017123650A2 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102410078B1 (ko) * 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
LT3472207T (lt) 2016-06-20 2021-05-10 F-Star Delta Limited Surišančios molekulės, kurios suriša pd-l1 ir lag-3
JP7085708B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｌａｇ－３結合要素
AU2017290709A1 (en) * 2016-06-29 2019-01-24 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018050902A2 (en) 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
NZ751956A (en) 2016-09-23 2022-01-28 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
WO2018127710A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
KR102585848B1 (ko) 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
AU2018250641A1 (en) 2017-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
CA3059366A1 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
BR112020001944A2 (pt) * 2017-08-04 2020-08-04 Genmab A/S agente de ligação, ácido nucleico, vetor de expressão, célula, composição, métodos para tratamento de uma doença e para produção de um anticorpo biespecífico, uso de um agente de ligação, e, anticorpo anti-idiotípico.
CA3112990A1 (en) * 2017-08-16 2019-02-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US20230192897A1 (en) 2017-10-10 2023-06-22 Numab Therapeutics AG Multispecific antibody
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
MA50353A (fr) * 2017-10-10 2020-08-19 Numab Therapeutics AG Anticorps ciblant pdl1 et procédés d'utilisation associés
CA3082321A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137
US11673954B2 (en) * 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
TW201930355A (zh) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 結合物件(三)
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
EP3732197A1 (en) * 2017-12-28 2020-11-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019173798A1 (en) 2018-03-08 2019-09-12 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
CN111566127A (zh) * 2018-03-27 2020-08-21 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
JP2021528988A (ja) * 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
EP3820569A1 (en) 2018-07-12 2021-05-19 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
JP2021531785A (ja) 2018-07-24 2021-11-25 インヒブルクス インコーポレイテッド 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
PL3830120T3 (pl) * 2018-07-31 2023-10-09 Pieris Pharmaceuticals Gmbh NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1
TW202028246A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3單域抗體及其治療性組合物
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
JP2022504822A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
MX2021006379A (es) 2018-11-30 2021-10-13 Abl Bio Inc Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos.
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
AU2020296181A1 (en) * 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation
JP2022539527A (ja) * 2019-06-26 2022-09-12 エーピー バイオサイエンシーズ， インコーポレイテッド Ｔ細胞活性化のための抗体
JP2022553922A (ja) * 2019-10-11 2022-12-27 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4087866A1 (en) * 2020-01-09 2022-11-16 F. Hoffmann-La Roche AG New 4-1bbl trimer-containing antigen binding molecules
MX2022009091A (es) * 2020-02-04 2022-09-19 Genmab As Anticuerpos para usarse en terapia.
TW202136315A (zh) * 2020-03-20 2021-10-01 大陸商榮昌生物製藥（煙臺）股份有限公司 一種雙特異性融合蛋白及其應用
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
EP4154910A1 (en) 2020-06-30 2023-03-29 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CN114195900B (zh) 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023146394A1 (en) * 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023205793A2 (en) * 2022-04-22 2023-10-26 Inhibrx, Inc. Siglec-8 binding proteins and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532439A4 (en) * 2002-05-10 2006-10-18 Epitome Biosystems Inc UNIQUE RECOGNITION SEQUENCES AND METHODS OF USE IN PROTEIN ANALYSIS
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007100098A1 (ja) * 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
EP2066810A2 (en) * 2006-09-08 2009-06-10 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
AU2008200389A1 (en) * 2007-09-10 2009-03-26 Commonwealth Scientific And Industrial Research Organisation Insect olfactory receptors and ligands therefor
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20110262348A1 (en) * 2010-03-29 2011-10-27 Vrije Universiteit Brussel Selective targeting of intratumoral cells
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN106102774A (zh) * 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
MX2019007144A (es) * 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.

Also Published As

Publication number Publication date
RU2018128601A (ru) 2020-02-13
IL304871A (en) 2023-10-01
JP2022062146A (ja) 2022-04-19
US20230416387A1 (en) 2023-12-28
SG11201805532XA (en) 2018-07-30
EP3402823A4 (en) 2019-09-18
US20170198050A1 (en) 2017-07-13
IL260530B1 (en) 2023-09-01
CN108779176A (zh) 2018-11-09
SG10201912405TA (en) 2020-02-27
IL260530B2 (en) 2024-01-01
KR20180096789A (ko) 2018-08-29
MX2018008308A (es) 2019-05-15
AU2017207742B2 (en) 2022-03-17
EP3402823A2 (en) 2018-11-21
US10501551B2 (en) 2019-12-10
JP7022993B2 (ja) 2022-02-21
CA3009661A1 (en) 2017-07-20
AU2022200918A1 (en) 2022-03-03
RU2018128601A3 (pt) 2020-06-17
JP2019504831A (ja) 2019-02-21
WO2017123650A2 (en) 2017-07-20
US11566078B2 (en) 2023-01-31
AU2017207742A1 (en) 2018-07-12
US20200199243A1 (en) 2020-06-25
WO2017123650A3 (en) 2017-09-08
IL260530A (pt) 2018-08-30

Similar Documents

Publication Publication Date Title
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
BR112018013911A2 (pt) proteínas de fusão de ligação a ox40 multivalentes e multiespecíficas
BR112018001161A2 (pt) proteínas de fusão de ligação a gitr multiespecíficas e multivalentes
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
BR112018000584A2 (pt) proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
AR123115A1 (es) Composiciones y métodos para la degradación selectiva de proteínas
CL2018000042A1 (es) Anticuerpos de unión a tau
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112018013883A2 (pt) membros de ligação com domínios de arcabouço de diversidade alterada
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112018014150A2 (pt) anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos
CL2018000043A1 (es) Anticuerpos de unión a tau
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
EA201792662A1 (ru) Специфические антитела к т-клеточному рецептору
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EA201892440A1 (ru) Антитела к tl1a и их применения
CL2018000824A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
BR112017008011A2 (pt) métodos baseados em proximidade para seleção de parceiros de ligação
BR112015028082A2 (pt) ensaio de internalização de receptor de sabor

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: INHIBRX, INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]